Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink
This article was originally published in The Pink Sheet Daily
Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.
You may also be interested in...
Cancer Drug Cull By NHS Sparks Demands For NICE Reform
Disappointed by NHS England’s decision to remove a number of high-cost drugs from the Cancer Drugs Fund, the U.K. pharma industry is focusing its firepower on reforming NICE appraisals.
U.K. Cancer Drug Fund May Shift To ‘Coverage With Evidence Development’-Style Approach
Fund would revaluate benefits – and pricing – of drugs it covers, adding extra layer of complexity to accessing new medicines for Britain’s cancer patients.
U.K. Coverage Rejection Of Alimta In NSCLC Increases Concerns About Access To Cancer Drugs
The U.K.’s NICE has rejected reimbursement under the National Health Service for Lilly’s Alimta in non-small cell lung cancer on cost grounds, prompting renewed calls to update or replace the U.K. Cancer Drugs Fund.